ACLS experienced a meaningful revenue contraction in fiscal 2025, with top-line declining approximately 17.6% year-over-year, driving substantially lower operating and net income.
The revenue decline from approximately $1.0B to $839.0M reflects continued softness in systems demand, with systems revenue falling from $782.6M to $571.0M — a notably sharper drop than the overall business — suggesting customers are deferring capital equipment purchases. While gross margin held essentially flat at 44.9% versus 44.7%, the lower revenue base flowed through to operating profit declining from $210.8M to $119.3M, a meaningful compression that investors should monitor closely heading into 2026. The company's near-complete revenue concentration in ion implantation (98.2%) leaves limited diversification buffer if end-market demand remains subdued.
Revenue declined roughly 17.6% to $839.0M and gross profit fell in line to $376.8M, yet gross margin held steady near 45%, indicating cost discipline even as volumes compressed. Operating income fell from $210.8M to $119.3M and net income declined from $201.0M to $120.2M, both reflecting meaningful deleverage as fixed costs were spread over a smaller revenue base rather than any gross margin deterioration. On the balance sheet, cash edged up modestly to $145.5M and inventory rose 16.6% to $329.0M — a build worth watching as it could signal either demand optimism or slowing shipments — while operating cash flow contracted modestly to $118.3M, leaving the company still solidly cash-generative but with less financial flexibility than the prior year.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Net income declined 40.2% — review whether driven by operations, interest costs, or non-recurring items.
Cash grew 17.8% — improving liquidity position supports investment and shareholder returns.
Revenue softened 17.6% — monitor whether this is cyclical or structural.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Inventory built 16.6% — monitor whether demand supports this build or if write-downs may follow.
Current assets declined 16.1% — monitor working capital adequacy and short-term liquidity.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →